Abbott’s trial win for patent infringement by DexCom’s CGM systems still doesn’t have information on damages awarded due a hung jury.

The company remained tight-lipped on the biomarker driving high response rates for its CDK9 inhibitor SLS009 from a Phase II trial, as a Phase III interim analysis for its AML cancer vaccine galinpepimut-S draws near.

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

The two diabetes players announced a new integration between their products.